Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

Bibliography

• Sabaté EE. Adherence to long-term therapies: evidence for action. World Health Organization; Geneva, Switzerland: 2003
   Google Scholar
• Brandes DW, Callender T, Lathi E, O’Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009;25:77-92
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:S24-40
   PubMed Web of Science ®Google Scholar
• Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
   PubMed Web of Science ®Google Scholar
• Al-Sabbagh A, Bennet R, Kozma C, et al. Medication gaps in disease- modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol 2008;255:S79
   Web of Science ®Google Scholar
• Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14
   PubMedGoogle Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012;15:601-9
   PubMedGoogle Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225
   PubMedGoogle Scholar
• de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence 2012;6:263-73
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Fox RJ, Salter AR, Tyry T, et al. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Int J MS Care 2013;15:194-201
   PubMedGoogle Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-32
   PubMed Web of Science ®Google Scholar
• Brochet B, Lemaire G, Beddiaf A; et l’Epicure Study Group. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Rev Neurol 2006;162:735-40
   PubMedGoogle Scholar
• Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 2006;113:156-62
   PubMed Web of Science ®Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005;11:585-91
   PubMed Web of Science ®Google Scholar
• Lesaux J, Jadback G, Harraghy CE. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis. J Neurosci Nurs 1999;31:174-9
   PubMedGoogle Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis–results of the betaPlus observational cohort study. J Neurol Sci 2011;307:120-6
   PubMed Web of Science ®Google Scholar
• Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence 2011;5:173-80
   PubMed Web of Science ®Google Scholar
• Bayas A, Japp G, Fulda U, et al. Injection devices in the basic therapy of multiple sclerosis. Survey among neurologists, MS nurses and patients. Nervenheilkunde 2010;29:57-62
   Google Scholar
• Devonshire VA, Verdun di Cantogno E. Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis. Ther Deliv 2011;2:1455-65
   PubMedGoogle Scholar
• Lugaresi A. RebiSmart (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv 2013;10:273-83
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012;52:275-301
   PubMed Web of Science ®Google Scholar
• Singer B, Wray S, Miller T, et al. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Mult Scler Relat Disord 2012;1:87-94
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 2012;12:7
   PubMed Web of Science ®Google Scholar
• Hupperts R, Becker V, Friedrich J, et al. Multiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv 2015;12:15-25
   PubMed Web of Science ®Google Scholar
• Guimaraes J, Sa MJ. Cognitive dysfunction in multiple sclerosis. Front Neurol 2012;3:74
   PubMedGoogle Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3
   PubMed Web of Science ®Google Scholar
• D’Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence 2012;6:55-61
   PubMed Web of Science ®Google Scholar
• Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol 2010;10:28
   PubMed Web of Science ®Google Scholar
• O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007;29:1128-45
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009;15:219-28
   PubMed Web of Science ®Google Scholar
• De Stefano N, Curtin F, Stubinski B, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Mult Scler 2010;16:888-92
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53
   PubMed Web of Science ®Google Scholar
• Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197-206
   PubMed Web of Science ®Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MSMRIAG. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:33-41
   PubMed Web of Science ®Google Scholar
• De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci 2012;312:97-101
   PubMed Web of Science ®Google Scholar
• Wray S, Armstrong R, Herrman C, et al. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin Drug Deliv 2011;8:1543-53
   PubMed Web of Science ®Google Scholar